A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
← catalyst calendarNCT07142343 · readout in 1,273 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
5estimated
Sites
1
Country
Turkey (Türkiye)
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-19 | actual | When the study began enrolling |
| Primary completion | 2030-02-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-02-12 | estimated | The whole study's end, after follow-up |
| First posted | 2025-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- CHAPLE Disease
Intervention
- Drug: Pozelimab — also filed as VEOPOZ
Primary outcomes
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Event (TEAEs)
measured Through week 52
Severity of TEAEs
measured Through week 52
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed